ROS1 Plus Breakapart
The ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) gene at 6q22 is an ALK (anaplastic lymphoma receptor tyrosine kinase) gene paralogue which encodes a type I integral membrane protein with tyrosine kinase activity1.
ROS1 rearrangements define a molecular subset of non-small cell lung cancer (NSCLC) and are seen in approximately 2% of patients with NSCLC2. A number of partner genes have been identified, including SLC34A2, CD74 and SDC43. It has been shown that these ROS1 fusions activate the pSTAT3, PI3K/AKT/mTOR and SHP-2 phosphatase pathways4,5.
NSCLC patients with ROS1 rearrangements have been shown to respond to treatment with ALK/MET tyrosine kinase inhibitors, such as crizotinib6.
ROS1 rearrangements with the GOPC (golgi associated PDZ and coiled-coil motif containing) gene fusion partner were originally reported in glioblastoma, but have now also been detected on cholangiocarcinoma, ovarian cancer and NSCLC patient samples7-9.
The ROS1 Plus design covers the ROS1 region and the region deleted in ROS1-GOPC fusions.
1. Matsushime H et al., Mol Cell Biol 1986;6:3000-4
2. Bergethon K et al., J Clin Oncol 2012;30(8):863-70
3. Davies KD et al., Cancer Res 2012;72(8):1538-7445
4. Birchmeier C et al., Proc Natl Acad Sci 1987;84:9270-9274
5. Ou SH et al., Expert Rev Anticancer Ther 2012;12(4):447-56
6. Shaw, A.T. et al., 2014. 371(21), pp.1963–71.
7. Gu TL et al., PLoS One 2011;6: e15640
8. Charest A et al., Genes Chromosomes Cancer 2003;37:58-71
9. Davies KD & Doebele RC, 2013. Clinical cancer 19(15), 4040–4045
- Area of Interest*
- Lung Cancer
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.